FDA Calendar • Benzinga benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Precigen Reports First Quarter 2021 Financial Results
- Company on track to achieve stated 2021 milestones -
- Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy -
- Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) -
- Upcoming presentation at FOCIS Virtual Annual Meeting to provide clinical progress for AG019 ActoBiotics™ in Type 1 diabetes (T1D) -
News provided by
Share this article
Share this article
GERMANTOWN, Md., May 10, 2021 /PRNewswire/ Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2021 financial results.
Search jobs 08-Apr-2021 Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update
Preliminary Phase 1b Data
- Gedatolisib showed a potentially differentiated safety and tolerability profile -
Corporate Update
- Proceeds from first $15 million tranche increase cash-on-hand to $44 million -
- Drug development capabilities and team broadened and expanded -
- Conference call and webcast scheduled for today, April 8 at 5 p.m. Eastern Time -
MINNEAPOLIS (BUSINESS WIRE) Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today reported preliminary data for the 103 patients enrolled in the expansion portion of an ongoing Phase 1b clinical trial evaluating gedatolisib, a first-in-class PI3
Με τον Ευθύμη Ρεντζιά συναντήθηκε ο αντιπεριφερειάρχης Νίκος Λιούπας kosmoslarissa.gr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kosmoslarissa.gr Daily Mail and Mail on Sunday newspapers.
Trial Suggests Russia s COVID-19 Vaccine is 91.6% Effective
Feb 02, 2021 10:41 AM
873 views
Staff Writer
Preliminary Phase 3 trial results from Russia s Sputnik V vaccine shows that it s 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease.
The trial also found that the 2,144 people over the age of 60 tolerated the vaccine well, and the vaccine had a similar efficacy of 91.8%. Out of the total 19,866 participants, 16 cases of symptomatic Covid-19 were confirmed in the vaccine group 21 days after the first vaccine dose. Sixty-two cases were found in the placebo group, which equated to efficacy of 91.6%.
There were also no adverse reactions associated with the vaccine, while mild symptoms were found, including pain at the injection site, flu-like symptoms, and low energy levels. The trial is currently ongoing and is aiming to include a total of 40,000 participants, including a more diverse panel of participants, as most of the p